Cortexin
unknown riskAlso: Cortexin-5 · Cortexin-10 · Cortex polypeptide · Polypeptides of cerebral cortex
Cortexin is a Russian-developed neuropeptide bioregulator derived from bovine cerebral cortex. It contains a complex mixture of low-molecular-weight polypeptides and amino acids with established neurotrophic and neuroprotective properties. Approved in Russia for a range of neurological conditions including stroke, TBI, and cognitive decline, Cortexin is one of the Khavinson bioregulator peptides — a class of organ-specific regulatory peptides developed in Soviet-era research. Not FDA-approved; not available in the US through licensed channels.
Reported Benefits
Neuroprotection and stroke recovery
Russian RCTs demonstrate improved neurological outcomes and reduced infarct size after ischemic stroke; methodology rated moderate quality.
Traumatic brain injury
Clinical studies from Russia show accelerated neurological recovery in TBI patients treated with Cortexin IM.
Cognitive function (age-related decline)
Open-label and placebo-controlled studies report improved memory and attention in patients with vascular or age-related cognitive impairment.
Antioxidant / anti-apoptotic effects
Preclinical evidence shows reduction in lipid peroxidation, caspase activation, and oxidative neuronal damage; robust in animal models.
Mechanism of Action
Cortexin's polypeptide mixture penetrates the blood-brain barrier and acts on cortical neurons through multiple pathways: stimulation of BDNF and NGF synthesis, inhibition of lipid peroxidation, reduction of excitatory amino acid (glutamate) toxicity, modulation of GABAergic and dopaminergic neurotransmission, and activation of anti-apoptotic pathways. Khavinson's bioregulator theory proposes that organ-specific peptides extracted from a given tissue carry regulatory signals that restore homeostasis in that same tissue type.
Key Clinical Studies
Gusev EI et al. (2012)
Randomized, controlled · 72
Cortexin 10 mg/day IM for 10 days improved neurological function scores in acute ischemic stroke versus standard care
Shamalov NA et al. (2010)
Randomized, double-blind, placebo-controlled · 120
Cortexin reduced neurological deficit and improved daily function at 3 months post-stroke
Khavinson VK et al. (2002)
Preclinical · Animal (rodents)
Cortexin peptides upregulate BDNF and NGF gene expression in cerebral cortex neurons
Overview
Cortexin is a Soviet-developed, Russian-approved neuropeptide bioregulator with a longer clinical history than nearly any peptide used in Western functional medicine. Developed in the 1970s–80s at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson, it belongs to a class of tissue-specific peptide bioregulators derived from corresponding organs — in Cortexin’s case, the bovine cerebral cortex. It has been approved in Russia for decades and is on formulary at major Russian neurological centers. Outside Russia, it is largely unknown in mainstream medicine but has a following in the biohacking and integrative neurology communities.
Evidence
The clinical trial record for Cortexin consists primarily of Russian-language publications from Russian research institutions, which creates both a geographic bias concern and a translation/accessibility barrier. The methodological quality varies, but several placebo-controlled trials in stroke and TBI populations show measurable neurological improvements. The preclinical mechanistic literature is more robust — multiple papers document neurotrophic factor induction, anti-apoptotic signaling, and antioxidant effects in rodent models. While the evidence base is real, it has not been independently replicated in Western academic centers with modern trial design.
Regulatory Status / Clinical Use
Cortexin is manufactured by Geropharm (Saint Petersburg, Russia) and is approved by Russia’s Roszdravnadzor for neurological conditions. It is not FDA-approved, not EMA-approved, and not available through US licensed compounding. In Russia, it is administered by IM injection in hospital and outpatient settings, often in 10-day cycles. Western access is through grey-market international sources, which carry significant regulatory risk.
Bottom Line
Cortexin is scientifically credible within the limits of its evidence base, but geographically siloed. For practitioners in Russia and former Soviet states, it is standard neurological care. For US practitioners, it is a research compound with no regulatory pathway and uncertain supply chain. The Khavinson bioregulator concept — organ-specific peptide homeostasis — is intriguing and partially supported by mechanistic data, but remains outside mainstream Western scientific consensus.
✦ Sponsored
Stop Guessing About Your Health. Start Optimizing It.
Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.
Learn More →
Regulatory Status
RestrictedNot FDA-approved; not 503A-listed; approved in Russia; restricted/unapproved in US and EU
Safety Profile
Side Effects
- •Local injection site reactions
- •Allergic reactions (rare; bovine origin)
- •Headache (transient, rare)
Contraindications
- •Bovine protein allergy
- •Epilepsy (use with caution)
- •Pregnancy (insufficient data)
Drug Interactions
- •CNS stimulants (additive effect possible)
- •Antiepileptic drugs (interaction uncertain)
Primary Uses
Related Peptides
Planning a protocol?
Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Cortexin?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →